Search Results

Brain–computer interface company Precision Neuroscience Corporation announced the launch of two new clinical study sites, at Mount Sinai Health System and Perelman School of Medicine at the University of Pennsylvania.

This webinar explores the pivotal role of patent data in overcoming the data challenges faced by generative AI models in drug discovery, particularly for biologics. Watch now.

Synchron , the brain-computer interface (BCI) company developing endovascular technology to restore functionality in patients with motor impairment, today announced the launch of a community-centered BCI registry to bring patients, carers and clinicians together to learn how BCI is being designed to provide benefit to people with limited mobility.

Blue Arbor Technologies Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the RESTORE™ Neuromuscular Interface System for people with upper limb loss.

With the FDA’s approval, Fasenra will compete with GSK’s Nucala, which in December 2017 became the first biologic approved for eosinophilic granulomatosis with polyangiitis.